J Clin Pharmacol Ther. 2025;6(2):JCPT-06-1073 | Open Access
Hui He, Yanping Gou, Xueying Bai and Di Shen
A 59-year-old man was treated with amlodipine benazepril tablets for hypertension. Perilabial edema occurred 24 hours after treatment and was not taken seriously. The next day, amlodipine Benazepril tablets were taken again and aggravated perilabial edema with laryngeal edema occurred. Considering the adverse reaction of amlodipine benazepril tablets, the drug was stopped immediately and the corresponding symptomatic treatment was given. After 10 ... Read more
CASE REPORT Updated Jun 07, 2025 PDF
J Clin Pharmacol Ther. 2025;6(2):JCPT-06-1072 | Open Access
Zhijian Lin, Yu Wang, Xiaomeng Zhang and Bing Zhang
This technical comment discusses the value and challenges of avian models in the study of hyperuricemia and gout, highlighting their physiological similarities to humans and their potential for advancing biomedical research. The convergent evolution of uricase deficiency in avians and humans, makes these models particularly relevant for studying conditions like hyperuricemia and gout. The comment emphasizes the advantages of avian ... Read more
REVIEW ARTICLE Updated Jun 03, 2025 PDF
J Clin Pharmacol Ther. 2025;6(1):JCPT-06-1070 | Open Access
Lingyu Li, Le Zhu, Mo Chen, Tianchen Yang, Ya Zhao and Zhiyu Shao
Background: Epiphyllum oxypetalum (DC.) Haw. is a plant of great ornamental value. In recent years, it has been gradually used in food and cosmetics, especially in cosmetics. Aims: Delve into the ingredients of E. Oxypetalum (DC.) Haw. to explore their beauty effects.
Methods: The ingredients of E. Oxypetalum (DC.) Haw. were isolated and purified by HLB ... Read more
RESEARCH ARTICLE Updated May 03, 2025 PDF
J Clin Pharmacol Ther. 2025;6(1):JCPT-06-1069 | Open Access
Vishal Rastogi, Riya Mahar, R1Amity Institute of Pharmacy, Indiaavi Maurya, Nithya Shanthi and Priyanka Saroj
Biosimilars are biologic drugs highly similar to an already approved reference biologic. They are transforming advanced therapeutic areas by increasing patient access to these drugs and lowering their costs. Guidelines for biosimilars have been established around the world but can be inconsistent and often reflect the inherent challenges associated with the adoption of biosimilars. For example, the first comprehensive biosimilar ... Read more
REVIEW ARTICLE Updated May 02, 2025 PDF
J Clin Pharmacol Ther. 2025;6(1):JCPT-06-1068 | Open Access
Sam T Donta
Lyme Disease is an infectious disease that may become a persistent illness. The causative organisms are sensitive in vitro to many antibiotics, but there are numerous patients with persisting symptoms that have had difficulty resolving those symptoms with standardly recommended antibiotic treatments. Herein is described the pharmacologic basis for the successful treatment of persistent Lyme disease, using ... Read more
REVIEW ARTICLE Updated Apr 17, 2025 PDF